Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group.
<h4>Background</h4>The WHO recommended 1200mg/day of fluconazole (FCZ) in the induction phase of cryptococcal meningitis (CM) in HIV prior to 2018 in regions where amphotericin-B (AMB) was unavailable. A 2-stage AMB-controlled, dose-escalation study to determine the maximum tolerated dos...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0281580 |
| _version_ | 1827862904913788928 |
|---|---|
| author | Umesh G Lalloo Lauren Komarow Judith A Aberg David B Clifford Evelyn Hogg Ashley McKhann Aggrey Bukuru David Lagat Sandy Pillay Vidya Mave Khuanchai Supparatpinyo Wadzanai Samaneka Deborah Langat Eduardo Ticona Sharlaa Badal-Faesen Robert A Larsen ACTG A5225 Team |
| author_facet | Umesh G Lalloo Lauren Komarow Judith A Aberg David B Clifford Evelyn Hogg Ashley McKhann Aggrey Bukuru David Lagat Sandy Pillay Vidya Mave Khuanchai Supparatpinyo Wadzanai Samaneka Deborah Langat Eduardo Ticona Sharlaa Badal-Faesen Robert A Larsen ACTG A5225 Team |
| author_sort | Umesh G Lalloo |
| collection | DOAJ |
| description | <h4>Background</h4>The WHO recommended 1200mg/day of fluconazole (FCZ) in the induction phase of cryptococcal meningitis (CM) in HIV prior to 2018 in regions where amphotericin-B (AMB) was unavailable. A 2-stage AMB-controlled, dose-escalation study to determine the maximum tolerated dose and the safety/efficacy of an induction-consolidation strategy of higher doses FCZ (1200mg-2000mg/day), adjusted for weight and renal function (eGFR)in adults with CM was undertaken.<h4>Methods</h4>In Stage-1, three induction doses of FCZ (1200mg/day, 1600mg/day and 2000mg/day) were tested in sequential cohortsand compared with AMB in a 3:1 ratio. A particular dose was not tested in Stage 2 if there were significant predetermined safety or efficacy concerns. In Stage-2, the 1200mg dose was excluded per protocol because of increased mortality, and participants were randomised to 1600mg, 2000mg FCZ or AMB in a 1:1:1 ratio.<h4>Findings</h4>One hundred and sixty eight participants were enrolled with 48, 50, and 48 in the AMB, 1600mg and 2000mg cohorts. The Kaplan Meier proportion for mortality (90% CI) at 10 and 24 weeks for AMB was 17% (10, 29) and 24% (15, 37), compared to 20% (12, 32) and 30% (20, 43) for 1600mg, and 33% (23, 46) and 38% (27, 51) for 2000mg/day FCZ. With the exception of a higher incidence of gastrointestinal side effects in the 2000mg cohort, both induction doses of FCZ were safe and well tolerated. There were no life-threatening changes in electrocardiogram QTc which were similar across all doses of FCZ and AMB. The median (IQR) change in log10 cryptoccal colony forming units (CFU) from week 0 to week 2 was -8(-4.1,-1.9) for AMB; -2.5(-4.0, -1.4) for 1600mg FCZ and -8 (-3.2, -1.0) for 2000mg FCZ. The proportion (90% CI) CSF CM negative at 10 weeks was 81%(71,90) for AMB; 56%(45,69) for 1600mg FCZ and 60%(49,73) for 2000mg FCZ.<h4>Interpretation</h4>Induction phase weight and renal-adjusted doses of 1600mg and 2000mg/day FCZ for CM were safe and well tolerated except for increased GI side effects in the 2000mg/day dose, and had similar times to achieve CSF sterilization, but took significantly longer than AMB. The WHO recommended 1200mg FCZ was associated with a high mortality. While not statistically significant, mortality was numerically lower in the AMB compared to 1600mg and 2000mg FCZ These data make a case for a phase 3 study of higher doses of FZC. |
| first_indexed | 2024-03-12T14:01:13Z |
| format | Article |
| id | doaj.art-d5c2b08341f74d62a664c9a9098c7601 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-03-12T14:01:13Z |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-d5c2b08341f74d62a664c9a9098c76012023-08-22T05:32:01ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01182e028158010.1371/journal.pone.0281580Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group.Umesh G LallooLauren KomarowJudith A AbergDavid B CliffordEvelyn HoggAshley McKhannAggrey BukuruDavid LagatSandy PillayVidya MaveKhuanchai SupparatpinyoWadzanai SamanekaDeborah LangatEduardo TiconaSharlaa Badal-FaesenRobert A LarsenACTG A5225 Team<h4>Background</h4>The WHO recommended 1200mg/day of fluconazole (FCZ) in the induction phase of cryptococcal meningitis (CM) in HIV prior to 2018 in regions where amphotericin-B (AMB) was unavailable. A 2-stage AMB-controlled, dose-escalation study to determine the maximum tolerated dose and the safety/efficacy of an induction-consolidation strategy of higher doses FCZ (1200mg-2000mg/day), adjusted for weight and renal function (eGFR)in adults with CM was undertaken.<h4>Methods</h4>In Stage-1, three induction doses of FCZ (1200mg/day, 1600mg/day and 2000mg/day) were tested in sequential cohortsand compared with AMB in a 3:1 ratio. A particular dose was not tested in Stage 2 if there were significant predetermined safety or efficacy concerns. In Stage-2, the 1200mg dose was excluded per protocol because of increased mortality, and participants were randomised to 1600mg, 2000mg FCZ or AMB in a 1:1:1 ratio.<h4>Findings</h4>One hundred and sixty eight participants were enrolled with 48, 50, and 48 in the AMB, 1600mg and 2000mg cohorts. The Kaplan Meier proportion for mortality (90% CI) at 10 and 24 weeks for AMB was 17% (10, 29) and 24% (15, 37), compared to 20% (12, 32) and 30% (20, 43) for 1600mg, and 33% (23, 46) and 38% (27, 51) for 2000mg/day FCZ. With the exception of a higher incidence of gastrointestinal side effects in the 2000mg cohort, both induction doses of FCZ were safe and well tolerated. There were no life-threatening changes in electrocardiogram QTc which were similar across all doses of FCZ and AMB. The median (IQR) change in log10 cryptoccal colony forming units (CFU) from week 0 to week 2 was -8(-4.1,-1.9) for AMB; -2.5(-4.0, -1.4) for 1600mg FCZ and -8 (-3.2, -1.0) for 2000mg FCZ. The proportion (90% CI) CSF CM negative at 10 weeks was 81%(71,90) for AMB; 56%(45,69) for 1600mg FCZ and 60%(49,73) for 2000mg FCZ.<h4>Interpretation</h4>Induction phase weight and renal-adjusted doses of 1600mg and 2000mg/day FCZ for CM were safe and well tolerated except for increased GI side effects in the 2000mg/day dose, and had similar times to achieve CSF sterilization, but took significantly longer than AMB. The WHO recommended 1200mg FCZ was associated with a high mortality. While not statistically significant, mortality was numerically lower in the AMB compared to 1600mg and 2000mg FCZ These data make a case for a phase 3 study of higher doses of FZC.https://doi.org/10.1371/journal.pone.0281580 |
| spellingShingle | Umesh G Lalloo Lauren Komarow Judith A Aberg David B Clifford Evelyn Hogg Ashley McKhann Aggrey Bukuru David Lagat Sandy Pillay Vidya Mave Khuanchai Supparatpinyo Wadzanai Samaneka Deborah Langat Eduardo Ticona Sharlaa Badal-Faesen Robert A Larsen ACTG A5225 Team Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group. PLoS ONE |
| title | Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group. |
| title_full | Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group. |
| title_fullStr | Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group. |
| title_full_unstemmed | Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group. |
| title_short | Higher Dose Oral Fluconazole for the Treatment of AIDS-related Cryptococcal Meningitis (HIFLAC)-report of A5225, a multicentre, phase I/II, two-stage, dose-finding, safety, tolerability and efficacy randomised, amphotericin B-controlled trial of the AIDS Clinical Trials Group. |
| title_sort | higher dose oral fluconazole for the treatment of aids related cryptococcal meningitis hiflac report of a5225 a multicentre phase i ii two stage dose finding safety tolerability and efficacy randomised amphotericin b controlled trial of the aids clinical trials group |
| url | https://doi.org/10.1371/journal.pone.0281580 |
| work_keys_str_mv | AT umeshglalloo higherdoseoralfluconazoleforthetreatmentofaidsrelatedcryptococcalmeningitishiflacreportofa5225amulticentrephaseiiitwostagedosefindingsafetytolerabilityandefficacyrandomisedamphotericinbcontrolledtrialoftheaidsclinicaltrialsgroup AT laurenkomarow higherdoseoralfluconazoleforthetreatmentofaidsrelatedcryptococcalmeningitishiflacreportofa5225amulticentrephaseiiitwostagedosefindingsafetytolerabilityandefficacyrandomisedamphotericinbcontrolledtrialoftheaidsclinicaltrialsgroup AT judithaaberg higherdoseoralfluconazoleforthetreatmentofaidsrelatedcryptococcalmeningitishiflacreportofa5225amulticentrephaseiiitwostagedosefindingsafetytolerabilityandefficacyrandomisedamphotericinbcontrolledtrialoftheaidsclinicaltrialsgroup AT davidbclifford higherdoseoralfluconazoleforthetreatmentofaidsrelatedcryptococcalmeningitishiflacreportofa5225amulticentrephaseiiitwostagedosefindingsafetytolerabilityandefficacyrandomisedamphotericinbcontrolledtrialoftheaidsclinicaltrialsgroup AT evelynhogg higherdoseoralfluconazoleforthetreatmentofaidsrelatedcryptococcalmeningitishiflacreportofa5225amulticentrephaseiiitwostagedosefindingsafetytolerabilityandefficacyrandomisedamphotericinbcontrolledtrialoftheaidsclinicaltrialsgroup AT ashleymckhann higherdoseoralfluconazoleforthetreatmentofaidsrelatedcryptococcalmeningitishiflacreportofa5225amulticentrephaseiiitwostagedosefindingsafetytolerabilityandefficacyrandomisedamphotericinbcontrolledtrialoftheaidsclinicaltrialsgroup AT aggreybukuru higherdoseoralfluconazoleforthetreatmentofaidsrelatedcryptococcalmeningitishiflacreportofa5225amulticentrephaseiiitwostagedosefindingsafetytolerabilityandefficacyrandomisedamphotericinbcontrolledtrialoftheaidsclinicaltrialsgroup AT davidlagat higherdoseoralfluconazoleforthetreatmentofaidsrelatedcryptococcalmeningitishiflacreportofa5225amulticentrephaseiiitwostagedosefindingsafetytolerabilityandefficacyrandomisedamphotericinbcontrolledtrialoftheaidsclinicaltrialsgroup AT sandypillay higherdoseoralfluconazoleforthetreatmentofaidsrelatedcryptococcalmeningitishiflacreportofa5225amulticentrephaseiiitwostagedosefindingsafetytolerabilityandefficacyrandomisedamphotericinbcontrolledtrialoftheaidsclinicaltrialsgroup AT vidyamave higherdoseoralfluconazoleforthetreatmentofaidsrelatedcryptococcalmeningitishiflacreportofa5225amulticentrephaseiiitwostagedosefindingsafetytolerabilityandefficacyrandomisedamphotericinbcontrolledtrialoftheaidsclinicaltrialsgroup AT khuanchaisupparatpinyo higherdoseoralfluconazoleforthetreatmentofaidsrelatedcryptococcalmeningitishiflacreportofa5225amulticentrephaseiiitwostagedosefindingsafetytolerabilityandefficacyrandomisedamphotericinbcontrolledtrialoftheaidsclinicaltrialsgroup AT wadzanaisamaneka higherdoseoralfluconazoleforthetreatmentofaidsrelatedcryptococcalmeningitishiflacreportofa5225amulticentrephaseiiitwostagedosefindingsafetytolerabilityandefficacyrandomisedamphotericinbcontrolledtrialoftheaidsclinicaltrialsgroup AT deborahlangat higherdoseoralfluconazoleforthetreatmentofaidsrelatedcryptococcalmeningitishiflacreportofa5225amulticentrephaseiiitwostagedosefindingsafetytolerabilityandefficacyrandomisedamphotericinbcontrolledtrialoftheaidsclinicaltrialsgroup AT eduardoticona higherdoseoralfluconazoleforthetreatmentofaidsrelatedcryptococcalmeningitishiflacreportofa5225amulticentrephaseiiitwostagedosefindingsafetytolerabilityandefficacyrandomisedamphotericinbcontrolledtrialoftheaidsclinicaltrialsgroup AT sharlaabadalfaesen higherdoseoralfluconazoleforthetreatmentofaidsrelatedcryptococcalmeningitishiflacreportofa5225amulticentrephaseiiitwostagedosefindingsafetytolerabilityandefficacyrandomisedamphotericinbcontrolledtrialoftheaidsclinicaltrialsgroup AT robertalarsen higherdoseoralfluconazoleforthetreatmentofaidsrelatedcryptococcalmeningitishiflacreportofa5225amulticentrephaseiiitwostagedosefindingsafetytolerabilityandefficacyrandomisedamphotericinbcontrolledtrialoftheaidsclinicaltrialsgroup AT actga5225team higherdoseoralfluconazoleforthetreatmentofaidsrelatedcryptococcalmeningitishiflacreportofa5225amulticentrephaseiiitwostagedosefindingsafetytolerabilityandefficacyrandomisedamphotericinbcontrolledtrialoftheaidsclinicaltrialsgroup |